Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma.
Antonio Nieto GarcíaTeresa Garriga-BarautAna María Plaza MartínMaría Nieto CidJavier Torres-BorregoMaría Del Mar Folqué GiménezJaime Lozano BlascoMontserrat Bosque GarcíaLaura Moreno-GalarragaMiguel Tortajada-GirbésCristina Rivas JuesasMaría Penín AntónMaría Araceli Caballero-RabascoMirella GaboliAlejandro Lopez-NeyraJuan Navarro MorónAndrea Freixa-BenaventeLaura Valdesoiro-NavarreteEsther Ballester AsensioVerónica Sanz SantiagoRaquel Romero GarcíaÁlvaro Gimeno-Díaz de AtauriAlfredo Valenzuela-SoriaMercedes Sánchez MateosJosé Batlles GarridoAnselmo Andrés-MartínElena Campos AlonsoCarmen Aragón FernándezElena Vázquez RodríguezLuz Martínez PardoGenoveva Del Río-CamachoÁngel Mazón RamosPublished in: Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2021)
In this large, long-term, observational study, moderate-to-severe exacerbations decreased significantly from the first year of treatment with omalizumab. The beneficial effect was maintained in the long term, along with a good safety profile. Our results position omalizumab as an effective long-term treatment in pediatric patients with severe persistent allergic asthma.